Component

Human DNA topoisomerase I / TOP1

Human DNA topoisomerase I / TOP1

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Apigenin reduced recombinant human topoisomerase-I DNA relaxation: over 30% inhibition at 10 micromolar and over 80% at 100 micromolar.

    Apigenin → Human DNA topoisomerase I / TOP1 Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_contrast
    {"intervention": "Apigenin concentration series", "comparator": "Vehicle", "endpoint": "Apigenin reduced recombinant human topoisomerase-I DNA relaxation: over 30% inhibition at 10 micromolar and over 80% at 100 micromolar.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    Cell-free DNA-unwinding/relaxation assay.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
    plain_language
    Apigenin reduced recombinant human topoisomerase-I DNA relaxation: over 30% inhibition at 10 micromolar and over 80% at 100 micromolar.
    primary_references
    Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894
    source_locator
    Reviewed reference api-top1-enzyme; Functional inhibition plus modeling does not supply an independently measured binding affinity.

    Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 708–714

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Cell-free DNA-unwinding/relaxation assay. · Recorded from source · Recorded from source

    ### api-top1-enzyme Apigenin reduced recombinant human topoisomerase-I DNA relaxation: over 30% inhibition at 10 micromolar and over 80% at 100 micromolar. Functional inhibition plus modeling does not supply an independently measured binding affinity. Model and exposure: Cell-free DNA-unwinding/relaxation assay. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | 2022 | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

  2. Apigenin did not detectably change TOP1 mRNA or protein in HT-29 cells despite the functional enzyme-assay effect.

    Apigenin → Human DNA topoisomerase I / TOP1 Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_contrast
    {"intervention": "Apigenin", "comparator": "Vehicle", "endpoint": "Apigenin did not detectably change TOP1 mRNA or protein in HT-29 cells despite the functional enzyme-assay effect.", "effect_direction": "no_detected_change", "combination": "single", "conditions": []} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    Human HT-29 cells; 30–60 micromolar apigenin, 48 hours.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
    plain_language
    Apigenin did not detectably change TOP1 mRNA or protein in HT-29 cells despite the functional enzyme-assay effect.
    primary_references
    Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894
    source_locator
    Reviewed reference api-top1-expression-null; Abundance and enzyme activity are distinct endpoints.

    Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 716–722

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Human HT-29 cells; 30–60 micromolar apigenin, 48 hours. · Recorded from source · Recorded from source

    ### api-top1-expression-null Apigenin did not detectably change TOP1 mRNA or protein in HT-29 cells despite the functional enzyme-assay effect. Abundance and enzyme activity are distinct endpoints. Model and exposure: Human HT-29 cells; 30–60 micromolar apigenin, 48 hours. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | 2022 | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.